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Highlights 
 
x Mitochondrial dysfunction is one of the earliest pathophysiological events 
in amyotrophic lateral sclerosis (ALS). 
x ALS-associated mutant proteins accumulate in mitochondria and cause 
mitochondrial damage 
x Mitochondrial dysfunction occurs at multiple levels, including 
mitochondrial respiration and ATP production, calcium handling, 
apoptotic signalling and mitochondrial dynamics. 
 
ABSTRACT 
Mitochondria are unique organelles that are essential for a variety of cellular processes 
including energy metabolism, calcium homeostasis, lipid biosynthesis, and apoptosis. 
Mitochondrial dysfunction is a prevalent feature of many neurodegenerative diseases 
including motor neuron disorders such as amyotrophic lateral sclerosis (ALS). 
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Disruption of mitochondrial structure, dynamics, bioenergetics and calcium buffering 
has been extensively reported in ALS patients and model systems and has been 
suggested to be directly involved in disease pathogenesis. Here we review the 
alterations in mitochondrial parameters in ALS and examine the common pathways to 
dysfunction. 
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1 Amyotrophic lateral sclerosis  
Motor neuron disease (MND) describes a group of neurological disorders 
characterised by the selective loss of motor neurons. Amyotrophic lateral sclerosis 
(ALS), the most common subtype of MND, is characterised by a progressive 
degeneration of both upper and lower motor neurons, resulting in muscle atrophy, 
gradual paralysis, and death, usually resulting from respiratory failure. ALS has a 
worldwide prevalence of 4-6 in 100,000, with differences noted between populations 
[1, 2]. The average age of onset is between 55-65 years of age, however familial cases 
are frequently associated with an earlier age of onset [3]. The average survival is 2-3 
years from diagnosis, with only 25% of patients surviving 5 years and 5-10% surviving 
10 years post-diagnosis [4].  
ALS clinically overlaps with frontotemporal dementia (FTD). FTD is a common cause 
of dementia in adults under the age of 65 that is characterised by neurodegeneration 
of the frontal and temporal cortex [5]. Around 50% of ALS patients display evidence of 
frontal and temporal lobe dysfunction on detailed neuropsychological testing and up to 
5-10% of ALS cases present with clinically diagnosed FTD. Similarly, while 
approximately 15% of FTD patients go on to develop ALS, about half display some 
degree of motor involvement [6].  
Approximately 10% of ALS cases follow a familial, mostly autosomal dominant 
inheritance pattern (familial ALS). The remaining 90% of cases have no clear genetic 
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basis (sporadic ALS). To date mutations in over 20 genes have been associated with 
ALS, including superoxide dismutase 1 (SOD1), TAR DNA binding protein (TARDBP; 
TDP-43), Fused in sarcoma (FUS), and C9orf72 (Table 1; [7]). Together mutations in 
these genes account for approximately 60% of familial ALS and 11% of sporadic ALS. 
In agreement with the clinical overlap between ALS and FTD, the GGGGCC (G4C2) 
repeat expansion mutation in C9orf72 was found to be the most common genetic 
cause of both ALS and FTD, accounting for approximately 40 and 25% of familial 
cases, respectively [8-10; reviewed in Ref. 11]. The genes affected in ALS have been 
implicated in a wide range of cellular pathways, suggesting that ALS is a multi-factorial 
disease. Possible pathogenic mechanisms underlying motor neuron degeneration 
include RNA toxicity, excitotoxicity, disruption of proteostasis, defective axonal 
transport, oxidative stress, and mitochondrial dysfunction [reviewed in Ref. 12].  
2 The role of mitochondria in ALS pathogenesis 
Mitochondria play a central role in cell survival and metabolism. In addition to their 
well-known role as producers of ATP via oxidative phosphorylation, mitochondria play 
important roles in phospholipid biogenesis, calcium homeostasis, and apoptosis. 
Mitochondria are of particular importance in neurons. Neurons have high metabolic 
requirements ± the brain FRQVXPHVRIWKHERG\¶VUHVWLQJ ATP production despite 
being only 2% of its mass [reviewed in Refs. 13, 14]. Moreover, mitochondria are 
essential calcium buffering organelles in neurons that modulate local calcium 
dynamics to, for example, modulate neurotransmitter release [reviewed in Ref. 15] . 
Neurons are long-lived cells that persist throughout the lifespan of the individual and 
as such are more susceptible to the accumulating damage arising from mitochondrial 
dysfunction [reviewed in Ref. 16]. Accordingly, the maintenance of a healthy pool of 
correctly localised mitochondria is essential for neuronal survival and function. It is not 
surprising therefore that mitochondrial dysfunction has been linked to a large number 
neurodegenerative disorders including ALS. Many of the identified ALS genes have a 
role in mitochondrial-associated functions (Table 1) and evidence gathered from in 
vitro and in vivo disease models and from patient studies strongly implicates the 
dysfunction of mitochondria as a core ALS disease component.  
ALS associated mitochondrial dysfunction comes in many guises, including defective 
oxidative phosphorylation, production of reactive oxygen species (ROS), impaired 
calcium buffering capacity and defective mitochondrial dynamics. Furthermore, with 
the possible exception RNA toxicity, mitochondrial dysfunction appears to be directly 
or indirectly linked to all of the postulated ³QRQ-PLWRFKRQGULDO´mechanisms of toxicity 
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associated with ALS, including excitotoxicity, loss of protein homeostasis and defective 
axonal transport.  
2.1 Structural evidence of damaged mitochondria 
Structurally altered and aggregated mitochondria, with a swollen and vacuolated 
appearance, were one of the first changes observed in ALS patient motor neurons [17, 
18] and in Bunina bodies [19]. Sporadic ALS cases occasionally additionally display 
axonal swellings consisting of neurofilament accumulations, swollen mitochondria and 
secondary lysosomes [20]. Morphologically abnormal mitochondria are also 
consistently reported in animal and cell models of ALS, with a tendency towards a 
fragmented mitochondrial population being observed. Expression of wild type or ALS 
mutant TDP-43 (M337V, Q331K, A315T) resulted in aggregated, fragmented and 
vacuolated mitochondria [21-23]. Overexpression of SOD1 G93A had similar effects 
and mitochondria were significantly less elongated and more spherical in motor 
neurons isolated from SOD1 G93A transgenic mice [24-26] and in vivo in motor 
neurons of early symptomatic SOD1G37R and SOD1G85R transgenic mice [27]. 
Furthermore, in SOD1 G93A transgenic mice mitochondria were found in abnormal 
clusters along the axon [22]. 
Overexpression of ALS mutant FUSR521G or R521H in cultured motor neurons 
resulted in mitochondrial shortening which was exacerbated by the presence of FUS 
in the cytosol [28]. Similar results were seen in both HT22 cells and primary cortical 
neurons expressing mutant FUS P525L which causes a juvenile form of ALS, and in a 
FUS P525L transgenic mouse model [29, 30]. Subtle fragmentation of the 
mitochondrial network has also been identified in fibroblasts of ALS patients with 
C9orf72 repeat expansions [31], and swollen mitochondria were reported in an iPSC 
model of C9orf72-associated ALS [32]. Aggregation of structurally altered 
mitochondria was reported in cortical neurons from Alsin knockout mice [33]. Similarly, 
mitochondria co-aggregated with TDP-43 in heterozygous knock-in mice bearing a 
ALS-associated R155H mutation in valosin-containing protein (VCP; also called p97, 
cdc48 in yeast ± further referred to as VCP/p97) [34, 35].  
Direct evidence that disruption of mitochondrial structure (and as a consequence 
function; see below) may contribute to the aetiology of ALS comes from the discovery 
of causative mutations in the mitochondrial protein CHCHD10 which is localised to 
contact sites between the inner and outer mitochondrial membrane [36]. ALS-
associated mutations in CHCHD10 disrupt mitochondrial cristae and have a profound 
effect on mitochondrial structure [37]. Deformation and loss of mitochondrial cristae 
have also been reported in C9ALS/FTD patient fibroblasts, in vitro and in vivo in SOD1 
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G93A, TDP-43A513T and FUS P525L ALS models and in Alsin knockout mice [29, 
31-33, 38, 39]. In SOD1 G93A and FUS P525L transgenic mice dilated cristae are 
already present at disease onset stage [30, 40]. 
Thus, mitochondrial structure and the mitochondrial network appears to be disrupted 
in most if not all models of familial ALS and in ALS patients. Moreover, the structural 
damage to mitochondria and fragmentation of the mitochondrial network was reported 
to occur in early disease stages in in vivo models of ALS indicating that mitochondrial 
morphological alterations occur potentially as an upstream source of degeneration 
rather than a consequence, and may contribute to ongoing degenerating phenotype 
[22, 23, 27]. 
2.2 ALS-associated proteins interact with mitochondria 
A number of proteins that have been linked to familial and sporadic ALS, including 
SOD1, TDP-43, FUS, C9orf72, and the C9orf72 GGGGCC repeat expansion-
associated glycine/arginine (GR) dipeptide repeat protein (DPR), have been shown to 
interact with mitochondria [29, 41-45]. The interaction of these ALS-associated 
proteins with the mitochondria appears to be instrumental to the induction of 
mitochondrial damage associated with ALS.  
Mutant SOD1 localises to the intermembrane space (IMS), where it has been shown 
to aggregate, and reduce the activity of the electron transport chain (ETC) complexes 
(see below) [46, 47]. Furthermore, SOD1 aggregates have been proposed to interfere 
with the activity of voltage-dependent anion channel 1 (VDAC1) which is responsible 
for the exchange of ATP, ADP and other respiratory substrates across the outer 
mitochondrial membrane (OMM) [reviewed in 48]. Direct interaction of ALS mutant 
SOD1 with VDAC1 inhibits channel conductance and reduces its permeability to ADP 
at both presymptomatic and symptomatic disease stages in the spinal cord of SOD1 
G93A transgenic rats. Furthermore, an approximately 25% reduction in VDAC1 activity 
accelerated disease in SOD1G37R transgenic mice [49]. Mutant misfolded SOD1 has 
also been and interact with Bcl-2 family proteins on the OMM, leading to pro-apoptotic 
changes (see below) [50]. 
TDP-43 and to a greater extend ALS mutant TDP-43 accumulates in mitochondria 
where it preferentially binds the mRNAs of the mtDNA-encoded complex I subunits 
ND3 and ND6 and causes complex I disassembly by impairing their transcription. 
Accumulation of ALS mutant TDP-43 in mitochondria appears to be mediated by 
internal mitochondrial targeting sequences in TDP-43 [42]. Since cytoplasmic TDP-43 
accumulation is a hallmark pathology in most ALS (but not SOD1 or FUS-related ALS), 
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this may also explain mitochondrial defects observed in sporadic ALS and other 
familial ALS cases.  
Both wild type FUS and ALS mutant FUS P525L co-purify with mitochondria and this 
is at least in part due to their interaction with the mitochondrial chaperone heat shock 
protein (HSP) of 60 kDa (HSP60) [29]. Mitochondrial localisation of FUS correlated 
with augmented ROS levels [29], and overexpression of FUS has been shown to 
reduce mitochondrial ATP production [51]. Reducing the association of FUS with 
mitochondria by ablating HSP60 expression ameliorated neurodegeneration in FUS 
transgenic Drosophila [29]. 
Several mitochondrial proteins have been identified as possible C9orf72-interacting 
proteins in a BioIP proteomics screen, including members of the IMM solute carrier 
family, VDAC3 and translocase of the inner mitochondrial membrane 50 (TIMM50). 
Furthermore, C9orf72 was detected in mitochondria-enriched fractions [44]. The 
relevance of this association is not yet clear. Another link between C9ALS/FTD and 
mitochondria comes from the finding that poly(GR) DPRs preferentially bind to 
mitochondrial ribosomal proteins [43]. 
2.3 Defective mitochondrial respiration and ATP production 
Reductions in cellular respiration and ATP production are well documented in ALS 
(Fig. 1). In post-mortem spinal cord of sporadic ALS patients the activity of all ETC 
complexes, complex I, II, III, and IV was found to be reduced [52, 53]. In addition, the 
activity of complexes I and IV were reported to be impaired in skeletal muscle [54-56] 
while complex I activity and ATP levels were reduced in lymphocytes of sporadic ALS 
patients [57]. Counterintuitively, in fibroblasts obtained from skin biopsies of sporadic 
ALS patients the mitochondrial membrane potential (MMP) was increased compared 
to healthy controls. Possibly the increased MMP observed in fibroblasts reflects an 
attempt to rescue inefficient ATP synthesis or the metabolic differences between skin 
fibroblasts and CNS cells [58]. Indeed, similar to fibroblasts obtained from sporadic 
patients, MMP was increased in C9orf72 patient fibroblasts [31] but was significantly 
decreased in iPSC-derived motor neurons reprogrammed from C9orf72 patient 
fibroblasts [32].  
In SOD1 G93A transgenic mice impaired ATP synthesis and depressed mitochondrial 
respiration rates in the brain and spinal cord were found well before disease onset and 
they persist throughout the course of the disease [39, 45]. Associated with these 
changes decreased complex I+III, II+III and IV activity were observed in the spinal cord 
of 17-week old symptomatic SOD1 G93A transgenic mice [45] and complex IV activity 
was reduced in forebrain mitochondria isolated from presymptomatic, symptomatic 
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and end-stage SOD1 G93A transgenic mice [39, 45]. Analysis of regional changes in 
ETC complex activities further showed a selective decrease of complex I and IV activity 
in the ventral horn of the spinal cord of these mice prior to the onset of disease which 
further declined as disease progressed [59]. In these cases, the reduced activity of 
complex IV may relate to impaired association of cytochrome c with the IMM 
membrane [39, 45]. A decrease in complex I activity was also confirmed in ex vivo 
motor cortex slices from SOD1 G93A mice [60] (Fig. 1). 
Analysis of mutant SOD1 ALS cell models recaptured the defects found in SOD1 G93A 
mice. SOD1I113T patient fibroblast lines showed reduced oxidative phosphorylation 
compared to non-disease controls [61]. Stable low level expression of SOD1 G93A or 
G37R in NSC-34 motor neuron-like cell lines reduced the activity of complex II and IV 
[62, 63] accompanied by reduced MMP [64] while doxycycline induced expression of 
SOD1 G93A, A4V, H46R, H80R, D90A, or D123H in the same cell line caused a 
decrease in complex I, II+III and IV activity which was accompanied by reduced cellular 
ATP levels [46]. In N2A neuroblastoma cells overexpression of SOD1G37R resulted 
in reduced complex I activity which correlated with a drop in MMP and reduced levels 
of cytosolic ATP, but complex II, III and IV activities were unaffected [63]. 
In contrast to these studies, Bowling et al. found increased complex I activity in post-
mortem frontal cortex of familial ALS patients with an SOD1 A4V mutation [65] and the 
same group reported an increase in complex I activity in the forebrain of SOD1 G93A 
transgenic mice [66]. Furthermore, when they assessed mitochondrial respiration 
solely via complex II, the mitochondrial respiration rate was not different in SOD1 G93A 
transgenic mice compared to wild type SOD1 transgenic mice [67]. Similarly, others 
found no evidence for reduced mitochondrial respiration via complex I or II in 
presymptomatic SOD1 G93A transgenic mice [68]. It is not readily apparent what 
accounts for the discrepancy between these studies, but these measurements are 
particularly sensitive to variations in experimental conditions and differences between 
the SOD1 G93A mouse strains cannot be excluded.  
Nevertheless, despite differences between studies and cell models, the overarching 
trend is that ALS mutant SOD1 decreases ETC activity and causes impaired ATP 
production. Moreover, the presymptomatic occurrence of oxidative phosphorylation 
disruption in SOD1 G93A transgenic mice suggests it may have a causative role in this 
ALS model. 
Defective mitochondrial respiration and ATP production have also been observed in 
models of non-SOD1 related familial ALS. Depolarisation of mitochondria was 
described in NSC-34 cells expressing wild type or mutant TDP-43 (Q331K and M337V) 
and primary motor neurons expressing TDP-43 M337V [21, 23, 69, 70]. In NSC-34 
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cells TDP-43-associated MMP reduction was accompanied by decreased complex I 
activity [70]. Similarly, in TDP-43 G298S and A382T patient fibroblasts reduced MMP 
was accompanied by decreased complex I activity, reduced oxygen consumption and 
decreased ATP levels [42]. However, this may not always be the case as others 
reported reduced MMP, but no changes in mitochondrial respiration or ATP content in 
3 independent TDP-43 A382T patient fibroblast lines [31]. 
As was the case for TDP-43, overexpression of wild type or mutant FUS P525L caused 
a reduction in MMP in HEK293 cells [29] and ATP production was impaired upon 
expression of wild-type or ALS mutant FUS R521C or R518K in NSC-34 cells [51]. 
Similarly overexpression of the sigma non-opioid intracellular receptor 1 (Sig1R) 
E102Q mutant in N2A cells reduced ATP production [71]. Decreased MMP was further 
observed in SQSTM1 knockout MEFs and in SH-SY5Y, mouse cortical neurons and 
astrocytes in which VCP/p97 expression was ablated using siRNA to model ALS-
associated loss of function mutants in p62/sequestosome1 and VCP/p97, respectively 
[72, 73]. In case of VCP/p97 the same results were obtained in VCP/p97 R155C, 
R155H and R191Q ALS patient fibroblast lines [73]. In these cell models of VCP/p97-
associated ALS the decrease in MMP was accompanied by a decrease in ATP levels 
but an increase in the rate of mitochondrial respiration and oxygen consumption, 
suggesting that depletion of MMP is due to uncoupling rather than ETC activity deficits 
[73]. Finally, analysis of fibroblasts from patients with mutations in the mitochondrial 
protein CHCHD10 revealed impaired ETC activity at complexes I, II, III and IV which 
was accompanied by a severe bioenergetics deficit [36, 37]. 
Neurons do not operate as isolated units, but depend on the surrounding cellular 
environment and supporting cells such as microglia and astrocytes for survival and 
function. Accordingly, it is now clear that ALS is a non-cell-autonomous disease with 
astrocytes in particular associated with disease progression [74, reviewed in Refs. 12, 
75]. One way in which glia support neurons is by shuttling of lactate, produced by 
conversion of the glycolysis product pyruvate, to the neighbouring neuron where it is 
converted back to pyruvate which is subsequently converted to acetyl-CoA and enters 
the Krebs cycle [76, reviewed in Ref. 77]. In fact, evidence suggests that glial lactate 
is the main energy source of neurons (i.e. the Astrocyte-Neuron Lactate Shuttle 
Hypothesis (ANLSH)). Several lines of evidence suggest that impairment of the 
ANLSH may be involved in the bioenergetics deficits observed in ALS. The expression 
of phosphoglycerate kinase 1 (PGK1) which transfers phosphate from 1,3-
bisphosphoglycerate (1,3-BPG) to ADP to produce 3-phosphoglycerate (3-PG) and 
ATP during glycolysis, as well as of the monocarboxylate transporter 4 (MCT4; 
Slc16a4), which is involved in the transport of lactate are downregulated in SOD1 
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G93A astrocytes [78]. Similarly, MCT1 (Slc16a1) expression is downregulated in 
oligodendrocytes in the spinal cord of SOD1 G93A transgenic mice. Furthermore, 
consistent with a possible role in neurodegeneration knock down of MTC1 caused 
motor neuron death in vivo [79]. Hence reductions in neuronal respiration and ATP 
production may be caused by failure of glia to provide respiratory substrates. 
Despite differences in mechanisms and specific observations depending on the 
models studied, decreased ETC activity and ATP levels emerge as a common feature 
in ALS. It is conceivable that, in line with the high energy demands of neurons, gradual 
depletion of ATP due to reduced respiration may trigger degeneration.  
2.4 Oxidative stress 
ROS are a natural by-product of oxidative phosphorylation. The ETC is responsible for 
the majority of ROS produced in a cell, with free radicals, mainly superoxide anion 
(O2Ú±), produced at complexes I, II and III as a result of incomplete, premature 
reduction of oxygen [reviewed in Refs. 80, 81] (Fig. 1). Dismutation of O2Ú±, a reaction 
catalysed by SOD1 and SOD2, gives rise to H2O2 which can further generate hydroxyl 
anions 2+Úby partial reduction. O2Ú± can also react with nitric oxide 12Ú to form 
peroxynitrite (ONOO±). ROS generated in cells can act as signalling molecules, but 
when excessively produced can lead to cellular damage to DNA, proteins and lipids 
and result in reduced efficiency of cellular processes, induction of inflammatory 
pathways, excitotoxicity, protein aggregation and endoplasmic reticulum (ER) stress 
or cell death [reviewed in Refs. 82, 83]. By proximity, mitochondria are particularly 
susceptible to ROS induced damage to mtDNA, proteins and lipids. Especially mtDNA 
appears vulnerable and this is exacerbated by limited DNA repair mechanisms in 
mitochondria. Resultant mitochondrial damage has been shown to affect mitochondrial 
function and is implicated in ageing [reviewed in Refs. 84, 85]. 
Increased levels of ROS and ROS-associated damage have been widely reported in 
ALS [reviewed in Ref. 86]. Increased markers of ROS damage have been found in 
biofluids of patients with sporadic ALS [87-90] as well as in post-mortem tissue [91-
94]. Similarly, increased ROS levels were reported in lymphoblasts of familial ALS 
cases with SOD1 mutations [95] and fibroblasts of patients with C9orf72 repeat 
expansions [31]. In contrast, analysis of lymphoblasts and fibroblast cell lines from 
sporadic ALS patients or familial ALS patients with a TDP-43 A382T mutation did not 
show evidence of increased ROS production or oxidative damage [31, 95-97], but 
some were more sensitive to 12Úgenerating chemicals [98]. Possibly specific culture 
conditions and respiratory substrates (glucose v galactose) used in these studies can 
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explain the variation in observations. Alternatively, peripheral tissues may not fully 
model CNS disease. 
Oxidative damage to DNA, RNA, proteins and lipids has been widely reported in SOD1 
G93A rodent models and cell models [reviewed in Ref. 86]. DNA and RNA appear to 
be especially vulnerable to oxidation, and mRNA oxidation has been shown to precede 
motor neuron degeneration and cause reduced expression of the encoded proteins in 
SOD1 G93A transgenic mice [94]. Interestingly mRNAs coding for ETC complexes and 
ATP synthase were selectively susceptible to oxidation [94]. Furthermore, SOD1 itself 
is a target of oxidative damage [99] and this has been linked to its misfolding and 
aggregation [100]. Since misfolded, aggregated SOD1 has been shown to disrupt 
mitochondrial function and increase superoxide production [49, 101, 102] a vicious 
cycle mechanism emerges in which mitochondrial damage and oxidative stress 
caused by misfolded SOD1 leads to exacerbation of SOD1 misfolding and downstream 
mitochondrial damage. Interestingly using monoclonal antibodies to misfolded SOD1, 
misfolded wild type SOD1 species have been shown to be present in sporadic ALS 
patients [103, 104] although this has been disputed by others [105]. 
Oxidative damage has also been proposed to promote aggregation of TDP-43 via 
cysteine oxidation and disulphide bond formation and acetylation [106, 107]. In 
agreement, treatment of COS-7 cells with 4-hydroxynonenal (HNE), which is produced 
in cells by lipid peroxidation, was shown to cause insolubilisation, phosphorylation, and 
partial cytosolic localisation of TDP-43 [108]. Overexpression of wild type and mutant 
TDP-43 M337V and Q331K or its C-terminal fragments in NSC34 have been shown to 
increase ROS and cause oxidative damage [21]. In addition to these deleterious 
effects TDP-43 also appears to have a protective function in response to oxidative 
stress. Indeed, oxidative stress has been shown to induce recruitment of TDP-43 to 
stress granules [109-111]. 
Other ALS-associated proteins that have been linked to oxidative stress include FUS 
P525L which has been shown to augment ROS levels when overexpressed in HEK293 
cells [29], and poly(GR) DPRs which have been shown to increase oxidative stress 
[43]. Interestingly as was the case for TDP-43, an oxidative environment increased 
FUS inclusions, again pointing toward a detrimental feed-forward loop [112]. 
2.5 Calcium mishandling 
Loss of calcium homeostasis has been observed in in vitro and in vivo models of 
mutant SOD1, vesicle-associated membrane protein-associated protein B (VAPB), 
TDP-43, and FUS-related ALS and in the motor nerve terminals ALS patients [51, 68, 
113-119]. In SOD1 G93A transgenic mice a significant decrease in mitochondrial 
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calcium loading capacity in the CNS was observed long before disease onset, 
suggesting an early loss of calcium buffering may be causal in disease [68]. Similarly, 
analysis of calcium handling in vulnerable hypoglossal motor neurons identified a 
reduction of uniporter-dependent mitochondrial calcium uptake which was not 
observed in resistant oculomotor neurons [120]. How these defects in mitochondrial 
calcium uptake affect motor neurons is not completely clear, but SOD1 G93A motor 
neurons show a delay in the recovery to basal level of the calcium increase following 
Į-amino-5-methyl-3- hydroxisoxazolone-4-propionate (AMPA) receptor activation 
[121]. 
Loss of ER±mitochondria communication has emerged as a major cause of loss of 
calcium homeostasis in ALS. An estimated 5±20% of mitochondria are closely 
associated with the ER at contact sites called mitochondria-associated ER membranes 
(MAM). Several protein complexes that tether ER to mitochondria have been 
proposed, including homo and heterotypic interactions between mitofusin (Mfn) 1 and 
2, interaction of inositol 1,4,5-trisphosphate receptor (IP3R) with VDAC via glucose-
regulated protein 75 (Grp75), and the integral ER protein VAPB that binds to protein 
tyrosine phosphatase-interacting protein 51 (PTPIP51) on the OMM (Fig. 2). Among 
other functions, ER±mitochondria contact sites allow calcium exchange between the 
two organelles [reviewed in Refs. 122, 123]. Disruption of ER±mitochondria 
interactions have been reported in mutant SOD1, Sig1R, TDP-43, and FUS-related 
ALS [51, 115, 124]. In the case of mutant TDP-43 and FUS-related ALS, reduced ER±
mitochondria communication was caused by a GSK3ß-dependent reduction in VAPB-
PTPIP51 interaction [51, 115]. In contrast, ALS mutant VAPBP56S was shown to have 
greater affinity for PTPIP51 and to increase ER±mitochondria association [118]. 
However, since in ALS8 patient-derived iPSC neurons VAPB expression is down-
regulated because of reduced expression of the VAPBP56S mutant allele [125], it is 
likely that in VAPBP56S-related ALS ER±mitochondria contacts are actually 
decreased as well. Whether VAPB±PTPIP51 interaction is also disrupted in mutant 
SOD1 and Sig1R-related ALS is not known, but in SIGMAR1 knockout mice which 
model loss of Sig1R function, the interaction between IP3R and VDAC was decreased 
in motor neurons [124]. Interestingly VAPB expression levels in the spinal cord of 
sporadic ALS cases are significantly lower compared to healthy controls [126]. Thus, 
disrupted ER±mitochondria communication may be a general feature in ALS.  
In ALS mutant FUS and TDP-43 models, impaired ER±mitochondria communication 
leads to reduced calcium uptake in mitochondria and an associated rise in cytosolic 
calcium upon triggering of calcium release from the ER [51, 115]. Similarly, in 
SIGMAR1 knockout mice cytosolic calcium levels were elevated and the time to return 
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to basal levels was significantly longer [124]. As mentioned above, similar loss of 
calcium homeostasis has been reported in SOD1 G93A transgenic mice. Whether 
these are due to reduced ER±mitochondria communication has not been formally 
shown, but neuronal overexpression of wild-type human VAPB has been shown to 
slow disease and increase survival in SOD1 G93A transgenic mice [127]. It is tempting 
to speculate, that restoring ER±mitochondria contacts is the basis of this protective 
effect. 
Dysregulation of calcium, possibly by miscommunication between ER and 
mitochondria, may be a primary cause of motor neuron death in ALS. Indeed, motor 
neurons possess several properties that make them more vulnerable to calcium 
dysregulation compared to other neuronal populations. They express a high number 
of calcium permeable AMPA receptors at the postsynaptic terminal, which results in a 
greater vulnerability to excitotoxicity thorough excessive calcium influx during 
excitatory neurotransmission events [117, 128, 129]. In addition, motor neurons have 
reduced cytosolic buffering capacity because they express low levels of calcium 
buffering proteins such as parvalbumin and calbindin D-28k and this makes them more 
dependent on mitochondria for calcium buffering [130-132, reviewed in Refs. 133, 
134]. Furthermore, loss of calcium homeostasis may contribute to a number of other 
ALS-associated toxic mechanisms, such as axonal transport defects and oxidative 
stress, and loss of protein homeostasis [135, 136, reviewed in Ref. 86]. Mitochondrial 
calcium regulates ATP production by activating the rate-limiting enzymes of the Krebs 
cycle and regulates oxidative phosphorylation and ATP synthesis to match local 
energy demand. As discussed above, reduced ATP production is a common feature 
in ALS. Diminished ATP levels may directly impact on axonal transport of 
mitochondria, vesicles and other cargoes by starving molecular motors of ATP. At the 
same time, elevated levels of cytosolic calcium may disrupt axonal transport of 
mitochondria by interacting with the mitochondrial kinesin-1 receptor Miro1 and in turn 
exacerbate axonal transport deficits and local ATP levels. Indeed, elevated cytosolic 
calcium levels were shown to disrupt axonal transport of mitochondria in ALS mutant 
VAPBP56S expressing neurons [114, reviewed in Ref. 135]. 
In ALS motor neurons, mitochondrial calcium overload may result from the 
physiological activity of AMPA receptors with pathologically increased calcium 
permeability. The resulting chronic calcium overload in mitochondria and concomitant 
abnormal oxidative phosphorylation has been shown to increase ROS production and 
oxidative stress [45, 137] . Mitochondrial calcium overload is predicted to result in 
depletion of calcium in the ER which causes protein misfolding and induces ER stress 
[reviewed in Refs. 133, 136]. Elevated cytosolic calcium levels activate calpain, which 
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has been shown to cleave TDP-43 to generate aggregation-prone fragments and could 
account for the TDP-43 pathology observed in ALS [138, 139]. Finally, chronic 
mitochondrial calcium overload and protein misfolding both induce apoptosis.  
2.6 Pro-apoptotic signalling 
Apoptosis is a last resort mechanism employed by cells upon suffering irreparable 
damage [reviewed in Ref. 140]. Apoptosis serves to remove a damaged cell from the 
environment in a controlled manner so as to not induce large-scale degeneration. 
Mitochondria are integral to apoptosis. Upstream apoptotic signalling cascades 
converge on mitochondria to bring about cytochrome c release, which activates 
downstream executioner caspases [reviewed in Ref. 140] (Fig. 3). Apoptosis is 
regulated by pro- and anti- apoptotic proteins of the Bcl-2 family, which control release 
of caspase-activating factors from mitochondria [reviewed in Refs. 140, 141]. 
Activation of apoptotic signalling cascades has been observed in most ALS models, 
but this is mostly an indirect consequence of other toxic events. However, ALS mutant 
SOD1 has been shown to directly influence apoptotic signalling by interaction with Bcl-
2. Wild-type and ALS mutant SOD1 (A4V, G37R, G41D and G85R) have been shown 
to bind the anti-apoptotic factor Bcl-2 in spinal cord samples [50]. When bound to 
mutant SOD1, the BH3 domain of Bcl-2 is exposed and this causes a pro-apoptotic 
gain of function of the Bcl-2 protein in both cell and animal models of mutant SOD1 
G93A ALS and in mutant SOD1 A4V patient spinal cord [142] (Fig. 3). The toxic mutant 
SOD1±Bcl-2 complex inhibits mitochondrial permeability to ADP and induces 
mitochondrial hyperpolarization due to reducing the interaction of SOD1 and VDAC1 
[143] (Fig. 3). 
2.7 Impaired mitochondrial dynamics 
Mitochondria are dynamic organelles that undergo fusion and fission events and 
undergo directed transport. Several lines of research indicate that impaired 
mitochondrial dynamics may contribute to the aetiology of ALS.  
2.7.1 Aberrant mitochondrial fission and fusion 
Mitochondria form a dynamic network that evolves according to the energetic 
requirements of the cell. An individual mitochondrion can fuse to or fission from the 
mitochondrial network in response to various cues [144]. Fusion allows mitochondria 
to share mitochondrial metabolites, DNA and proteins, and allows for dissipation of 
small changes in MMP. Fission facilitates mitochondrial motility and allows the isolation 
of damaged parts of the network prior to disposal by mitophagy. In healthy cells, 
mitochondrial network morphology is governed by the interplay between dynamin-
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related protein 1 (Drp1) and Fission 1 (Fis1) that promote fission, and Mfn1, Mfn2 and 
Optic atrophy 1 (Opa1) that promote fusion [reviewed in Ref. 145] (Fig. 4). Evidence 
points towards imbalances in these two opposing pathways in ALS.  
In SOD1 G93A expressing SH-SY5Y and NSC-34 cell models, a decrease in Opa1 
and increase in Drp1 levels resulting in a fragmented mitochondrial network were 
reported [146]. In vivo, the levels of Mfn1 and Opa1 progressively decreased while the 
levels of activated Drp1 phosphorylated at Ser616 and Fis1 remained stable in in the 
spinal cord of SOD1 G93A transgenic mice [147] (Fig. 4). In contrast, in SOD1 G93A 
mouse muscle fibres there was no reported change in Mfn1, Mfn2 or Drp1 levels [148]. 
Overexpression of wild type TDP-43 and to a greater extend ALS mutant TDP-43 
Q331K and M337V resulted in reduced mitochondrial length in primary motor neurons 
which was sensitive to Mfn2 levels [23]. Transgenic mice expressing wild type TDP-43 
exhibited increased levels of Fis1 and activated phosphor-Ser616 Drp1 and a 
reduction in Mfn1, which correlated with aberrant mitochondrial morphology and 
clustering [149]. In contrast, the same group reported no changes in the levels of 
phospho-Ser616 Drp1, Fis1 or Mfn1 in mutant TDP-43 M337V transgenic mice, 
despite a similar mitochondrial phenotype [150]. Possibly different pathways lead to 
fragmentation of the mitochondrial network in wild type and mutant TDP-43 transgenic 
mice, or, alternatively, external factors linked to disease such as changes in apoptotic 
factors result in mitochondrial fragmentation. Nevertheless, analysis of TDP-43 A382T 
patient fibroblasts showed that Fis1 levels were significantly increased compared to 
control cells [31] (Fig. 4). Counter-intuitively, mitochondrial network fragmentation in 
C9ALS/FTD patient fibroblasts was associated with an increase in Mfn1 levels [31]. 
Possibly Mfn1 expression is increased to compensate for dysregulation of other fusion 
and fission factors. 
Mitochondria±ER contact sites have been shown to regulate mitochondrial 
morphology. Mitochondrial fission occurs at ER±mitochondria contact sites where ER 
tubules wrap around and constrict mitochondria to aid division [151]. As discussed 
above reduced ER±mitochondria contacts are a common observation in various ALS 
models. Consistent with reduced fission, decreased ER±mitochondria contacts in 
motor neurons of SIGMAR1 knockout correlated with elongated mitochondria 
compared to controls [124] whereas, in VAPB P56S overexpressing cells increased 
ER±mitochondria contacts correlated with fragmented mitochondria [118] (Fig. 4). 
However, in SOD1, TDP-43 and FUS ALS models reduced ER±mitochondria contacts 
appear to correlate with fragmented mitochondria [23, 26, 51, 115, 152, 153]. 
Therefore, there is no straightforward correlation between ALS-associated disruption 
of ER±mitochondria contacts and changes in mitochondrial network morphology.  
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The relevance of exacerbated mitochondrial fission in the aetiology of ALS is not clear. 
Perhaps, smaller mitochondria, which tend to be less energetically favourable and 
more prone to accumulating ROS induced damage if they cannot fuse back to the 
network [154], may exacerbate mitochondrial damage. Thus, the fragmented 
mitochondrial network observed may correlate directly with the reduced MMP, ATP 
levels and increased ROS reported in ALS. Alternatively, mitochondrial fragmentation 
may merely reflect mitophagy, a physiological quality control response to mitochondrial 
damage (see below). Indeed, it is well established that one of the first steps of 
mitophagy is to isolate damaged mitochondria from the mitochondrial network 
[reviewed in Ref. 155]. However, as disease progresses and mitochondrial damage 
accumulates, mitophagy may become unable to cope and as a consequence 
mitochondrial fragmentation could become self-propagating. In any case, evidence 
suggests that mitochondrial fragmentation participates in ALS. Inhibition of 
mitochondrial fission by overexpression of dominant negative Drp1 K38A rescued 
SOD1 G93A induced mitochondrial fragmentation and trafficking defects as well as 
motor neuron viability [156]. Similarly, Promotion of mitochondrial fusion by co-
expressing Mfn2 in wild type or TDP-43 M333V expressing primary motor neurons 
rescued mitochondrial fragmentation [23]. Whether rescuing mitochondrial network 
morphology is sufficient to improve neuron survival in vivo remains unclear. 
2.7.2 Disrupted mitochondrial quality control 
As discussed above, accumulation of fragmented, rounded mitochondria is a common 
feature in ALS, and may indicate failure of mitophagy to clear damaged mitochondria. 
The molecular mechanisms of mitophagy have been reviewed in detail elsewhere 
[157], but briefly, loss of MMP results in accumulation of full length PINK1 on the OMM 
where it phosphorylates ubiquitin, which in turn promotes the recruitment of the E3 
ligase Parkin. Parkin ubiquitinates and promotes the VCP/p97-dependent degradation 
of various OMM proteins such as Mfn1/2 and Miro1 to isolate and immobilise the 
damaged mitochondrion. Ubiquitinated mitochondria are then recognised by the 
canonical autophagy machinery and are delivered to the lysosome for degradation 
(Fig. 5).  
TDP-43 and FUS directly regulate the expression of Parkin [158, 159]. Loss of TDP-
43 or FUS was shown to decrease Parkin levels [158], and consistent with loss of TDP-
43 function in the nucleus decreased Parkin protein levels were observed in sporadic 
ALS spinal cord motor neurons containing cytoplasmic TDP-43 aggregates [158]. 
Parkin protein levels were found to be decreased in TDP-43 A513T transgenic mice 
[38] but this was not observed by others [160]. Thus, since cytosolic TDP-43 
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aggregation is a near universal phenomenon in ALS, loss of parkin may impair 
mitophagy in most ALS cases. Furthermore, since, as discussed above, TDP-43 
accumulates in mitochondria and causes mitochondrial damage, a two-hit scenario 
emerges in which loss of mitophagy exacerbates the consequences of mitochondrial 
damage. Of note, Parkin has been shown to ubiquitinate TDP-43 and to promote its 
translocation from the nucleus to the cytosol in an HDAC6-dependent process [160]. 
Even though the latter is likely to be a reflection of the role of parkin and HDAC6 in 
aggrephagy rather than mitophagy, it does emphasise a close link between Parkin and 
TDP-43 that merits further examination. 
The Type II AAA+ ATPase VCP/p97 is involved in a multitude of processes, but its 
main function is to dislodge damaged ubiquitinated proteins from large protein 
complexes and membranes for degradation by the proteasome [reviewed in Refs. 161, 
162]. VCP/p97 is recruited to the OMM of damaged mitochondria following parkin 
recruitment and extracts ubiquitinated Mfn1 and 2 from the OMM to allow their 
degradation by the proteasome [163]. As such VCP/p97 is essential for mitophagy 
[164]. Missense mutations in VCP/p97 cause of 1-2% of familial ALS cases as well as 
inclusion body myopathy (IBM) with Paget's disease (PDB) and frontotemporal 
dementia (FTD) [165, 166]. Although it is not known exactly how disease-associated 
mutations in VCP/p97 alter its cellular functions, most mutations appear to convey 
varying degrees of loss of function [reviewed in Ref. 167]. Consistent with loss of 
function, MEFs expressing mutant VCP/p97 A232E do not clear mitochondria following 
damage, despite labelling with Parkin [164]. As discussed above, pathogenic 
mutations in VCP/p97 induce mitochondrial uncoupling and impair ATP production 
[73]. Possibly, this phenotype is caused by accumulation of damaged, uncoupled 
mitochondria that should have been degraded.  
Interestingly, not unlike Parkin, VCP/p97 has been linked to TDP-43 metabolism. In 
SHSY-5Y cells expressing mutant VCP/p97 (R95G, R155H/C, R191Q, A232E) TDP-
43 redistributed from the nucleus to the cytoplasm [168]. Similarly, in VCP/p97 R152H 
or A229E transgenic Drosophila and spinal cord motor neurons of VCP/p97 R155H or 
A232E transgenic mice expression of mutant VCP/p97 induced TDP-43 pathology 
[169]. Furthermore, in Drosophila, TBPH, the fly homolog of TDP-43 was identified as 
a genetic modifier that suppressed mutant VCP/p97 toxicity, indicating that VCP 
toxicity is at least in part mediated by a toxic gain of function of TDP-43 [169]. We now 
know that TDP-43 accumulates in mitochondria and causes damage to the ETC (see 
above; [42]). Hence a possible explanation for this genetic interaction is that 
accumulation of cytoplasmic TDP-43 exacerbates loss of mitochondrial quality control 
by mutations in VCP/p97.  
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Mitophagy requires autophagy receptors such as optineurin and p62/sequestosome-1 
that accumulate on ubiquitinated mitochondria and deliver them to the autophagosome 
by interaction with LC3-II on autophagic membranes. Optineurin and 
p62/sequestosome-1 are substrates of tank-binding kinase 1 (TBK1); phosphorylation 
by TBK1 promotes ubiquitin and LC3 binding and enhances mitophagy [reviewed in 
Refs. 170, 171;172].  
Mutations in the OPTN, SQSTM1 and TBK1 genes which encode optineurin, 
p62/sequestosome-1, and TBK1, respectively, have been associated with ALS [173-
175, reviewed in Ref. 11] (Table 1). ALS-associated mutations in these genes appear 
to cause loss of function phenotypes. The ALS-associated optineurin E478G mutation 
maps to the ubiquitin binding domain of optineurin and the mutant protein is no longer 
recruited to damaged mitochondria [176, 177]. Along the same lines, the ALS-
associated L341V mutation in p62/sequestosome-1 maps to the LC3-interacting 
region (LIR) domain and disrupts interaction with LC3 [178]. The ALS mutant forms of 
TBK1, TBK1 del690-713 and E696K, prevent the interaction between TBK1 and 
optineurin and impair clearance of LC3 labelled autophagic cargos [179, 180]. If ALS-
associated TBK1 mutants also affect mitophagy remains to be determined, but the role 
of TBK1 in mitophagy is well established. Furthermore, the activation of TBK1 is 
dependent on the activity of the upstream activity of PINK1/Parkin which as discussed 
above is affected in ALS [179, 180]. Consistent with failure to deliver damage 
mitochondria to the lysosome, LC3-II positive mitochondrial aggregates have been 
observed in wild type and ALS mutant TDP-43 Q331K and M337V expressing NSC-
34 cells as well as in SOD1 G93A mouse spinal cord [21, 181]. In case of SOD1 G93A 
the observed failure to clear damaged mitochondria appears to be caused by 
lysosomal deficits caused by impairment of retrograde trafficking of late endosomes 
rather than specific mitophagy deficits [182].  
Interestingly TBK1 has also been found to interact with C9orf72 in complex with 
SMCR8 and WDR41, and C9orf72 controls autophagy via regulation of the small Rab 
GTPases Rab1a, Rab8a and Rab39b [183-186, reviewed in Ref. 187]. Another ALS 
and autophagy-associated regulator of small Rab GTPases is Alsin, a guanine 
nucleotide exchange factor (GEF) for Rab5. Loss-of-function mutations in Alsin cause 
a recessive juvenile form of ALS, ALS2 [188, 189]. Loss of Alsin in mice impairs 
autophagy and corticospinal motor neurons exhibit fused mitochondria engulfed by 
vacuole structures consistent with failure to remove damaged mitochondria by 
mitophagy [33, 190]. Interestingly loss of Alsin in corticospinal motor neurons 
correlated with a progressive decline in Rab1a levels suggesting a direct link to 
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C9orf72 [33]. Thus, a number of ALS-associated insults appear to converge on 
autophagy and mitophagy. 
2.7.3 Impaired axonal transport of mitochondria 
Motor neurons are highly polarised cells and require membrane-bound vesicles, 
organelles, proteins, lipids and RNA to be transported from the soma to the axon 
terminal and vice versa. Impaired axonal transport of mitochondria is a well-
documented phenomenon in ALS. In fact, axonal transport defects are one of the 
earliest pathophysiological events in ALS motor neurons, indicating that they may be 
a primary cause of motor neuron loss [reviewed in Refs. 135, 191].  
Long distance transport of mitochondria is mediated by the molecular motors kinesin-
1 (previously referred to as conventional kinesin or KIF5) and cytoplasmic dynein that 
move along microtubules. Kinesin-1 moves toward the faster growing plus end of 
microtubules whereas cytoplasmic dynein moves toward the opposite minus end. 
Because axonal microtubules are uniformly orientated with their plus ends pointing 
away from the cell body, kinesin-1 transports mitochondria toward the axon terminal 
(anterograde transport) and cytoplasmic dynein ferries mitochondria to the cell body 
(retrograde transport) (Fig. 6). 
Defects in both anterograde and retrograde transport of mitochondria have been 
reported in a number of in vitro and in vivo experimental models. ALS mutant SOD1 
G93A, A4V, G85R or G37R caused reduced anterograde but not retrograde axonal 
transport of mitochondria in cultured cortical neurons and an identical phenotype was 
observed in embryonic motor neurons isolated from SOD1 G93A transgenic mice [26]. 
Similarly, overexpression of the ALS mutant VAPBP56S caused a selective block in 
anterograde transport of mitochondria [114]. Reduced overall mitochondrial transport 
was observed in primary motor neurons expressing wild-type TDP-43 and to a greater 
extent ALS mutant TDP-43 Q331K or M337V [23] and in Sig1R deficient motor 
neurons [124]. Interestingly, normal levels of axonal transport of mitochondria were 
reported in cortical neurons expressing wild type or mutant TDP-43 M337V or A315T 
at 5ದ7 days in culture, suggesting a possible cell type specificity [192]. Subsequent 
time-lapse recordings in single axons in the intact sciatic nerve of presymptomatic 
SOD1 G93A and TDP-43 A315T transgenic mice and rats confirmed deficits axonal 
transport of mitochondria in vivo [22, 193-195].  
Mitochondrial transport defects result in redistribution of mitochondrial in axons. In 
vitro, the number of axonal mitochondria was significantly reduced and the remaining 
mitochondria were spaced further apart in primary neurons expressing ALS mutant 
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SOD1 [26]. In vivo the number of axonal mitochondria was reduced in motor neurons 
of early symptomatic SOD1 G37R and SOD1 G85R transgenic mice and the motor 
axon terminals of SOD1 G93A transgenic rats and TDP-43 transgenic mice [27, 194, 
196]. Furthermore, the distribution of the remaining mitochondria was no longer 
homogeneous throughout the axons, with abnormal mitochondrial clusters observed 
along the axon [22, 27, 196, 197]. Similar mislocalisation and aggregation of 
mitochondria has been observed in the soma, dendrites and proximal axons of motor 
neurons in spinal cord sections from ALS patients, suggesting that disruption to 
mitochondrial transport is a general phenomenon in ALS [18]. 
A number of possible mechanisms underlying mitochondrial axonal transport defects 
have been proposed. In rare cases, pathogenic mutations in the axonal transport 
machinery, such as cytoplasmic dynein, kinesin-1 and Į-tubulin directly disrupt axonal 
transport. In most cases however the disruption of axonal transport of mitochondria 
appears to be indirect; proposed mechanisms include microtubule destabilisation, 
pathogenic kinase signalling, protein aggregation, and mitochondrial damage 
[reviewed in Ref. 135]. Axonal transport of mitochondria is controlled by the integral 
OMM protein Miro1 [reviewed in Ref. 198]. Miro1 is an atypical Rho GTPase comprised 
of two GTPase domains separated by two calcium-binding E-helix-loop-F-helix (EF)-
hand motifs [199]. Miro1 is anchored in the OMM and connects mitochondria to 
kinesin-1 and cytoplasmic dynein via the adapter proteins TRAK1 and 2 [200-205]. 
Miro1 regulates mitochondrial trafficking in response to physiological calcium stimuli 
and mitochondrial damage. Binding of calcium to the Miro1 EF-hand motifs modulates 
the interaction of kinesin-1 with Miro1 and impedes anterograde transport of 
mitochondria [206, 207]. During mitophagy, PINK1 phosphorylates Miro1 in response 
to mitochondrial damage [208-210]. Phosphorylation marks Miro1 for Parkin-
dependent proteasomal degradation and results in detachment of kinesin-1 from 
mitochondria and arrested mitochondrial movement [209]. 
As discussed above, mitochondrial calcium handling is dysregulated in ALS. Hence 
ALS-associated mitochondrial axonal transport defects may be the direct result of 
aberrant calcium-mediated regulation of Miro1. In agreement with such a mechanism, 
cytosolic calcium levels are elevated in cellular ALS models and in motor neurons from 
transgenic ALS models [114, 119] and, at least in case of VAPB P56S there is direct 
evidence that elevated calcium disrupts transport of mitochondria via Miro1 [114] (Fig. 
6). Similarly, ALS mutant SOD1, TDP-43, and Sig1R-associated reductions in ER±
mitochondria contacts result in transiently elevated cytosolic calcium levels due to 
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reduced calcium-uptake in mitochondria that coexist with axonal transport deficits, but 
the possible involvement of Miro1 remains to be determined [115, 124, 152]. 
Decreased levels of Miro1 have been reported in SOD1 G93A and TDP-43 M337V 
transgenic mice, as well as in the spinal cord of ALS patients [211]. Since both SOD1 
G93A and TDP-43 M337V damage mitochondria (see above), these results suggest 
that ALS-associated mitochondrial damage leads to halting of mitochondrial transport 
via PINK1/Parkin-dependent degradation of Miro1. 
In some cases, ALS-associated proteins may directly affect the axonal transport 
machinery. Both TDP-43 and FUS have been shown to regulate the expression of 
several kinesins, including kinesin-1, and TDP-43 binds TRAK1 mRNA [159, 212, 213]. 
ALS-mutant SOD1 directly binds to cytoplasmic dynein in SOD1 G93A and G37R cell 
and mouse models and the interaction becomes more prevalent through disease 
progression [214-216]. Thus, in case of mutant SOD1, axonal transport defects may 
in part be due to sequestration of dynein.  
There are several ways in which defective axonal transport of mitochondria may 
contribute to disease. Defective axonal transport of mitochondria may lead to 
imbalances in ATP generation and calcium buffering at the post-synaptic terminal. In 
conjunction with mitochondrial damage this may cause the dying back of the axon, a 
feature implicated in ALS [217] (Fig. 6). Retrograde transport defects are associated 
with defects in the removal of damaged organelles by mitophagy, which could explain 
the mitochondrial aggregates found in the axons of ALS patients [20, 218]. 
Furthermore, defective axonal transport of mitochondria may also affect the transport 
of other axonal cargoes such as signalling endosomes which appear closely linked to 
ALS pathology [reviewed in Ref. 135]. 
3 Mitochondria as therapeutic targets in ALS  
Finding a cure for ALS has thus far been unsuccessful. Targeting mitochondrial 
dysfunction presents an attractive treatment option due to the widespread prevalence 
of mitochondrial dysfunction in disease. Potential therapeutic strategies have aimed to 
decrease ROS generation, increase mitochondrial biogenesis, inhibit apoptotic 
pathways or dampen excitotoxicity.  
The only FDA drug approved for use in ALS is Riluzole. However, Riluzole only 
extends survival by approximately 3-month. The mechanism by which Riluzole acts to 
improve survival is unclear. Some evidence suggests that Riluzole decreases ROS 
through induction of glutathione synthesis [219]. However little effect was observed on 
basal levels of ROS, and therefore Riluzole may only act in this way in the context of 
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elevated ROS levels. Riluzole has been found to display a range of effects on 
glutamatergic signalling at the synapse, leading ultimately to attenuation in calcium 
handling requirements. Indeed, treatment in vitro with Riluzole prevents motor and 
cortical neuron loss induced by sustained glutamate increase and elevated ROS levels 
[220]. Furthermore, Riluzole has been demonstrated to reduce inward calcium currents 
and rescue the axonal transport of neurofilaments [221, 222]. Attenuation of inward 
calcium currents is predicted to alleviate stresses on cytosolic and mitochondrial 
calcium buffering mechanisms and potentially decrease cytosolic calcium levels with 
knock-on effects on ROS generation and mitochondrial function. However, with the 
limited effect on prognosis offered by Riluzole, alternative therapies are required for 
the treatment of ALS.  
Despite many drug-based and gene therapy approaches targeting mitochondrial 
dysfunction in ALS, neither treatments aimed at increasing mitochondrial function and 
survival nor those aimed at reducing oxidative stress have yielded significant results 
in clinical trials, despite early promising trials in animal models [223]. For example, 
several drugs targeting mitochondrial function and/or ROS such as Coenzyme Q10, 
Dexpramipexole, Olesoxime and Creatine all showed initial success in animal models 
but were unsuccessful in human clinical trials [224-231]. Reducing ROS using 
Edaravone, a free radical scavenger had initial success in mouse models but only a 
small decrease in human disease progression [232, 233]. Similarly, minocyline, an 
anti-apoptotic and anti-inflammatory drug which extended survival in mouse models, 
failed in a human phase III randomised trial [234]. The disparity between the results 
seen between initial studies mouse models and the results from human trials highlights 
the disparity between models and the human disease, and the need for better disease 
models [235]. In addition, the wide range of mitochondrial dysfunction in ALS means 
that a single therapy is unlikely to attenuate all aspects of dysfunction. Therefore, 
identifying which of the mitochondrial dysfunctions are relevant to disease causation 
and progression will continue to be important for the development of neuroprotective 
therapies in ALS. Targeting specific proteins dysregulated in ALS may provide 
alternative therapy avenues. Indeed a blocking peptide that prevents the abnormal 
interaction between mutant SOD1 and Bcl-2 has been shown to prevent apoptosis and 
improve mitochondrial function in SOD1 G93A transgenic mice [143].  
4 Conclusions 
Despite the surge in the number genes found to be associated with ALS since the turn 
of the millennium, the aetiology ALS remains largely unknown. Mitochondrial 
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dysfunction has emerged as a common, early phenomenon in ALS. The appearance 
of deficits in oxidative phosphorylation, calcium buffering and mitochondrial transport 
prior to the onset of disease symptoms in vivo in disease models suggests an important 
role for loss of mitochondrial integrity in the aetiology of ALS.  
Nevertheless, clinical trials targeting mitochondria have been disappointing, indicating 
that mitochondrial dysfunction alone may not be a primary cause of disease. Possibly 
the widespread presence of mitochondrial dysfunction in ALS models and patients, 
may be secondary to other disease-related insults such as protein aggregation and 
excitotoxicity. In such a scenario, mitochondrial function would gradually decay until a 
point-of-no-return threshold is reached and the motor neuron dies. Such a mechanism 
would be predicted to conspire with age-associated decline in mitochondrial function 
and may explain the late onset of the majority of ALS cases. In any case, since, with 
the possible exception of Riluzole, treatments targeting other proposed causes of ALS 
have been equally unsuccessful in clinical trials, it transpires that any successful 
therapeutic strategy may have to address multiple targets in a combination therapy. 
Importantly, mitochondrial dysfunction has also been widely reported in other 
neurodegeQHUDWLYH GLVHDVHV VXFK DV 3DUNLQVRQ¶V +XQWLQJWRQ¶V DQG $O]KHLPHU¶V
disease [236-238]. Similarities in defects in mitochondrial clearance and bioenergetic 
functions exist between these diseases and ALS despite different clinical presentation. 
Therefore, neurodegenerative conditions appear to be group of diseases with common 
dysfunction but with varying endpoints. Possibly discovery and study of common 
mechanisms underlying these diseases, including mitochondrial dysfunction, will 
increase our understanding of the essential requirements for neuronal survival that can 
inform future neuroprotective therapies. 
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Figure 1: Defective mitochondrial respiration, ATP production and oxidative 
stress 
The efficient activity of the electron transport chain is required for the generation of 
cellular ATP. The activity of the complexes involved in the electron transport chain 
have been shown to be decreased in SOD1, TDP-43 and CHCHD10-related ALS. This 
results in decreased MMP and ATP generation, and increased generation of ROS. 
See text for details. 
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Figure 2: Loss of calcium homeostasis 
Calcium homeostasis is achieved though the exchange of calcium between the ER 
and mitochondria at ER±mitochondria contacts. ER±mitochondria contacts are 
disrupted in SOD1, TDP-43, VAPB, Sig1R and FUS ALS. Disruption of the contacts 
may lead to increases in cytosolic calcium levels and disruption of calcium dependent 
cellular processes, including axonal transport, ATP generation and protein 
homeostasis. MCU, mitochondrial calcium uniporter. See text for details. 
 
 
Figure 3: Pro-apoptotic signalling 
Mitochondrial stress is increased due to dysfunctional cellular pathways resulting in 
increased ROS generation, and mitochondrial damage. Mutant SOD1 contributes to 
apoptotic signalling in ALS by binding the anti-apoptotic factor Bcl-2 and promoting a 
pro-apoptotic conformation of the protein. The Bcl2-SOD1 complex inhibits VDAC ADP 
permeability and induces mitochondrial hyperpolarisation. See text for details. 
 
 
Figure 4: Aberrant mitochondrial fission and fusion 
Mitochondrial network dynamics are required for correct mitochondrial function. 
Fission is mediated by Drp1, which is recruited to mitochondria by Fis1. Fusion of the 
OMM is mediated by Mfn1/2 and the fusion of the IMM by Opa1. Mitochondrial fission 
is promoted in SOD1 and TDP-43 ALS by increases in the fission factors Fis1 and 
Drp1 and a decrease in the fusion factors Mfn1 and Opa1. Decreased ER±
mitochondria contact sites may also lead to decreased mitochondrial fission events. 
Finally, dysfunctional removal of damaged organelles through the mitophagy pathway 
may also contribute to accumulation of fragmentation mitochondria. See text for 
details. 
 
 
Figure 5: Disrupted autophagy/mitophagy 
Mitophagy removes dysfunctional mitochondria from the cell. Mitochondria are 
exposed to high levels of stress due to elevations in ROS levels and aggregates of 
mutant ALS protein associated with mitochondria. Mitophagy is impaired at multiple 
stages in ALS. Mutant TDP-43 and FUS mislocalisation may affect parkin levels. The 
removal of ubiquitinated Mfn1/2 may be impaired by mutant VCP/p97. Recognition of 
ubiquinated mitochondrial cargos by nascent autophagosomes may be impaired by 
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mutations in p62/sequestosome-1, optineurin and TBK1. Other ALS genes such as 
SOD1, Alsin, and C9orf72 have also been linked to autophagy. See text for details. 
 
 
Figure 6: Disrupted axonal transport 
Neurons depend on axonal transport of mitochondria for their ATP requirement and 
calcium buffering. Axonal transport of mitochondria is impaired in ALS. Miro1, the 
OMM protein involved in mitochondrial trafficking, is reduced in SOD1 and TDP-43-
associated ALS. Mutant SOD1 binds the dynein/dynactin complex required for 
retrograde transport sequestering it in the cytosol. FUS and TDP-43 are proposed to 
regulate kinesin expression levels. Increases in cytosolic calcium levels due to 
decreased ER±mitochondria contacts in SOD1, TDP-43, FUS, Sig1R and VAPB-
related ALS may contribute to detachment of the mitochondria from kinesin, through 
aberrant Miro1 regulation. Loss of mitochondria from the axon terminal may lead to the 
dying back of the axon. See text for details. 
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Table 1: Impact of ALS-associated genes on mitochondrial function. Pathogenic variants of proteins implicated in ALS have been linked to 
altered mitochondrial function (Ref. http://alsod.iop.kcl.ac.uk/home.aspx; [7]) 
ALS locus Gene Protein Potential consequence of mutation on mitochondrial function 
ALS 1 SOD1 Cu, Zn superoxide dismutase 1 Mutant protein aggregates in IMS; decreased ATP generation; 
increased cellular ROS and ROS induced cellular damage; 
imbalance in calcium homeostasis and disruption of ER±
mitochondria contacts; induction of apoptosis via VDAC inhibition 
and Bcl-2 binding; disrupted mitochondrial architecture; impaired 
mitochondrial network dynamics and axonal transport; impaired 
mitochondrial clearance by mitophagy; disrupted ER±mitochondria 
contacts 
ALS 2 ALS2 Alsin Reduced autophagosome formation and decreased mitophagy 
ALS 6 FUS RNA-binding protein FUS Decreased ATP generation; increased ROS levels; loss of calcium 
homeostasis and disruption of ER±mitochondria contacts; reduced 
mitophagy-related gene expression; disrupted mitochondrial 
architecture; impaired mitochondrial transport via disrupted kinesin 
gene expression 
ALS 8 VAPB Vesicle-associated membrane 
protein-associated protein B 
Impaired calcium homeostasis and disrupted ER±mitochondria 
contacts; decreased anterograde axonal transport; disrupted ER±
mitochondria contacts 
ALS 10 TARDBP TAR DNA-binding protein 43 TDP-43 aggregates in mitochondria and disrupts mtDNA 
transcription; decreased ATP generation; impaired calcium 
homeostasis and disrupted ER±mitochondria contacts; disrupted 
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mitochondrial architecture; altered mitochondrial network dynamics 
and impaired mitochondrial axonal transport; reduced mitophagy 
related gene expression; impaired mitochondrial clearance by 
mitophagy 
ALS 12 OPTN Optineurin Reduced mitochondrial clearance by mitophagy 
ALS 14 VCP Valosin-containing protein Decreased ATP levels; mitochondrial uncoupling; reduced 
mitochondrial clearance by mitophagy 
ALS 16 SIGMAR1 Sigma non-opioid intracellular 
receptor 1 
Reduced ATP generation; disrupted ER±mitochondria contacts; 
dysregulated calcium homeostasis; reduced axonal transport 
ALS-FTD1 C9orf72 Chromosome 9 open reading 
frame 72 
DPR proteins interact with mitochondrial ribosomal proteins; altered 
MMP; increased cellular ROS levels; poly(GR) DPR induced 
oxidative stress; impaired autophagy; disrupted mitochondrial 
architecture and altered mitochondrial network dynamics 
ALS-FTD2 CHCHD10 Coiled-coil-helix-coiled-coil-helix 
domain containing 10 
Disrupted mitochondrial architecture; decreased electron transport 
chain activity  
ALS SQSTM1 p62/Sequestosome 1 Reduced mitochondrial clearance by mitophagy; reduced MMP 
Abbreviations: ATP - adenosine triphosphate; DPR - dipeptide repeat protein; IMS - intermembrane space; MAM - mitochondrial associated 
membrane; MMP - mitochondrial membrane potential; ROS - reactive oxygen species 
 
 
